Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Biofrontera Inc. (BFRI) vs InMed Pharmaceuticals Inc. (INM)

Biofrontera Inc. and InMed Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Biofrontera Inc. is the larger, with a market value of $17.8M against $7.7M — 2.3× the size. InMed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 19.4% against 17.8%. InMed Pharmaceuticals Inc. has the higher net margin (0.00% vs −13.8%) and the higher return on invested capital (0.00% vs −69.5%). Across the 17 metrics below, Biofrontera Inc. leads on 9 and InMed Pharmaceuticals Inc. on 8.

Valuation

Metric BFRI INM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.33 1.00 2.25
P/B 2.56 5.35 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.34 0.65 2.56
Earnings yield (38.14%) (218.43%) (2.99%)
Free cash flow yield (52.00%) (151.13%) 0.00%

Profitability

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Gross margin 79.25% 26.27% 53.94%
Operating margin (14.22%) 0.00% 0.00%
Net margin (13.78%) 0.00% 0.00%
Free cash flow margin (17.17%) 0.00% 0.00%
Return on equity (988.35%) (179.09%) (0.40%)
Return on assets (28.80%) (139.63%) (3.32%)
Return on invested capital (69.45%) 0.00% 0.00%

Growth

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% 19.38% 10.01%
EPS growth (last fiscal year) 67.70% 62.68% —
Revenue growth, 5-year CAGR 17.21% — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.00 0.05
Current ratio 1.18 1.37 2.31
Net debt to EBITDA 0.17 0.20 0.85

Dividend

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Market cap 17.82m 7.69m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack